Related Experiment Video
Updated: Jan 22, 2026

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
Current options and future possibilities for the systemic treatment of hepatocellular carcinoma
Jean-Luc Raoul1, Jean-Sébastien Frenel1, Judith Raimbourg1
1Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes 44805 Saint-Herblain, France.
Abstract:
Most hepatocellular carcinoma patients could not benefit from or experience disease recurrence after curative treatments. In 2007 sorafenib demonstrated efficacy in first line treatment of advanced hepatocellular carcinoma. After a decade of negative trials, in early 2019 we now have another tyrosine kinase inhibitor available in first line, lenvatinib, three other targeted therapies in second line post-sorafenib (regorafenib, cabozantinib and ramucirumab) and promising data from two immunotherapies (nivolumab and pembrolizumab). Unfortunately, no biomarkers have been identified to help guide our choice. In this short review we summarize the results of these different therapies and propose a therapeutic algorithm based on subgroup analysis. It is most likely that we will not have head-to-head comparisons in second line trials.
Insights
Advanced hepatocellular carcinoma treatment has new options like lenvatinib and immunotherapies. This review summarizes therapies and proposes an algorithm, as no biomarkers currently guide treatment choices for this cancer.
Area of Science:
- Hepatobiliary Cancers
- Medical Oncology
- Translational Research
Background:
- Hepatocellular carcinoma (HCC) often recurs after curative treatment.
- Sorafenib was the first targeted therapy for advanced HCC in 2007.
- Recent advancements include new tyrosine kinase inhibitors and immunotherapies.
Purpose of the Study:
- To review current first- and second-line therapies for advanced HCC.
- To propose a treatment algorithm based on subgroup analyses.
- To highlight the lack of predictive biomarkers for guiding therapy selection.
Main Methods:
- Literature review of clinical trials and subgroup analyses.
- Synthesis of data from targeted therapies and immunotherapies.
- Development of a proposed therapeutic algorithm.
Main Results:
- Lenvatinib is a new first-line option alongside sorafenib.
- Second-line options include regorafenib, cabozantinib, ramucirumab, nivolumab, and pembrolizumab.
- No validated biomarkers currently exist to direct treatment decisions.
Conclusions:
- A therapeutic algorithm is proposed to aid clinical decision-making in advanced HCC.
- Future research should focus on identifying biomarkers for personalized treatment.
- Head-to-head comparisons for second-line therapies are unlikely.
More Related Videos
05:06A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
Published on: October 24, 2015
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
Related Concept Videos
Electrical Current
Second Order systems II
First Order Systems
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...
Second Order systems I
By reinterpreting the system, one can derive the closed-loop transfer function, which...
Significance of Displacement Current
Current Trends in Nursing I